CRISPR gene editing (SCD)   Update: 30 May 2019 No update available.   Update: 29 March 2019 The Phase 1/2 Study in Sickle Cell Disease (SCD) is an open-label trial aiming to assess the safety and efficacy of a single dose of CTX001 in patients ages 18 to 35 with ...

  Update: 30 May 2019  Apotransferrinhas a physiological role in the transportation and distribution of iron among the body organs. Apotrasferrin has received orphan drug designation from EMA A proof of concept study in the Netherlands will begin in the second half of 2019 lasting 16 weeks with a maximum ...

This is how this year’s voting results were shaped: Universal access to quality thalassaemia healthcare services: Building bridges with and for patients (Winning theme, 196 votes) Patients’ voice at the frontline: Advocating for a better future in thalassaemia care and management (112 votes) The globalization of thalassaemia – Common challenges ...

POSTERS & BANNERS             SOCIAL MEDIA BANNERS        

VIT-2763   Update: 30 May 2019 No update available.    Update: 01 February 2019 A randomized, controlled, multi-centred phase 2 proof-of-concept trial will begin in the second half of 2019 to assess the effectiveness of the oral ferroportin inhibitor (VIT-2763) on iron overload in β-thalassaemia patients. Phase 1 trials have ...

  Update: 30 May 2019 No update available.   Update: 29 March 2019 SLN124 has been submitted to the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Subject to approval from the MHRA, Silence intends to begin a Phase I/II First-in-Human study in ß -Thalassemia and MDS patients, with the ...

  This is how this year’s voting results were shaped: Universal access to quality thalassaemia healthcare services: Building bridges with and for patients (Winning theme, 196 votes) Patients’ voice at the frontline: Advocating for a better future in thalassaemia care and management (112 votes) The globalization of thalassaemia – Common ...

Das epidemiologische Projekt des TIF konzentriert sich auf die Erhebung von Daten über Krankheitsträger, erwartete Geburten und den aktuellen Stand der Strategien zur Bekämpfung der Hämoglobinopathie in den Gesundheitssystemen der verschiedenen Ländern, die Mitglied der TIF sind. β- und α-Thalassämie, HbE und Sichelzellkrankheit (SCD) sowie Kombinationen bilden den Schwerpunkt dieser ...

Dies ist eines der neuen Projekte der TIF für das Jahr 2013, dessen Ziel es ist, eine Datenbank für Referenzzentren für Hämoglobinopathie auf der ganzen Welt einzurichten und eine Übersicht der Dienstleistungen zu erstellen, die sie für Patienten erbringen. Dies ist eine Erweiterung der Informationen des ENERCA-3-Projekts und der Beratungen ...